The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| OPHTHOTECH CORP | COM | 683745103 | 291,804 | 6,896,819 | SH | SOLE | 6,896,819 | 0 | 0 | ||
| VANGUARD INDEX FDS | TOTAL STK MKT | 922908769 | 303,183 | 2,979,100 | SH | SOLE | 2,979,100 | 0 | 0 | ||
| VANGUARD INTL EQUITY INDEX F | FTSE EUROPE ETF | 922042874 | 125,955 | 2,101,000 | SH | SOLE | 2,101,000 | 0 | 0 | ||
| WRIGHT MED GROUP INC | COM | 98235T107 | 18,393 | 585,759 | SH | SOLE | 585,759 | 0 | 0 | ||
| WRIGHT MED GROUP INC | RIGHT 03/01/2019 | 98235T115 | 7,033 | 4,720,065 | PRN | SOLE | 0 | 0 | 4,720,065 | ||
| TETRAPHASE PHARMACEUTICALS INC | COM | 88165N105 | 12,141 | 900,000 | SH | SOLE | 900,000 | 0 | 0 | ||
| AKEBIA THERAPEUTICS INC | COM | 00972D105 | 42,140 | 1,516,387 | SH | SOLE | 1,516,387 | 0 | 0 | ||
| INOGEN INC | COM | 45780L104 | 122,263 | 5,419,449 | SH | SOLE | 5,419,449 | 0 | 0 | ||
| FLEXION THERAPEUTICS INC | COM | 33938J106 | 24,037 | 1,783,131 | SH | SOLE | 1,783,131 | 0 | 0 | ||
| ALDER BIOPHARMACEUTICALS INC | COM | 014339105 | 64,248 | 3,201,183 | SH | SOLE | 3,201,183 | 0 | 0 | ||